This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by Joshua Korzenik, Brigham and Women's Hospital
Sponsor:
Information provided by (Responsible Party):
Joshua Korzenik, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT02424175
First received: April 18, 2015
Last updated: April 5, 2017
Last verified: September 2016
  Purpose
This is an open-label single-arm pilot study to measure the microbiological and clinical impacts of Fecal Microbiota Transplantation (FMT) in patients with Primary Sclerosing Cholangitis (PSC). The investigators will prospectively enroll 10 PSC patients Stage 1 and 2 who also have concurrent inflammatory bowel disease Donor Stool from one healthy donor will be obtained from OpenBiome. OpenBiome is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use

Condition Intervention Phase
Sclerosing Cholangitis Biological: Fecal Microbiota Transplantation Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

Resource links provided by NLM:


Further study details as provided by Joshua Korzenik, Brigham and Women's Hospital:

Primary Outcome Measures:
  • Comparison of microbiome pre and post transplant [ Time Frame: 12 weeks ]
    The investigators will analyze and compare the microbiome (bacterial populations) present pre- and post- transplant of the recipient. The investigators will also analyze the microbiome of the donor and compare it to the donor microbiome pre- and post-FMT.

  • Comparison of liver biochemistries pre and post transplant [ Time Frame: 12 weeks ]
    The primary study end point is them mean change serum liver biochemistries after 3 months of treatment as compared with baseline. Treatment success was defined as an improvement in serum alkaline phosphatase, total bilirubin, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) by 50 % or greater.


Secondary Outcome Measures:
  • Adverse event frequency [ Time Frame: 6 months ]
    Number of patients with reporting adverse events with type and severity of adverse events reported


Estimated Enrollment: 10
Study Start Date: January 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patients with PSC
This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
Biological: Fecal Microbiota Transplantation

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 or older
  2. Confirmed diagnosis of PSC (with a concurrent diagnosis of inflammatory bowel disease) characterized by a cholestatic liver condition of greater than 6 months duration with confirmatory cholangiographic findings, as well as an elevation of the serum alkaline phosphatase of greater than 1.5 times the upper limit of normal.

Exclusion Criteria:

  1. Decompensated liver disease
  2. Patients who were pregnant or breastfeeding
  3. Use of concomitant immune modulators including methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, thalidomide, Interleukin-10, or Interleukin-11 within 4 weeks prior to receiving the FMT
  4. Patients who are unable to give informed consent
  5. Patients who are unable or unwilling to undergo colonoscopy with moderate sedation (>ASA class II)
  6. Patients who have previously undergone FMT Patients who have a confirmed malignancy or cancer
  7. Patients who are immunocompromised
  8. Treatment within last 8 weeks with infliximab, adalimumab, certolizumab, natalizumab, vedolizumab or thalidomide
  9. Antibiotic use within 2-months of start date
  10. Participation in a clinical trial in the preceding 30 days or simultaneously during this trial
  11. Probiotic use within 30 days of start date
  12. Congenital or acquired immunodeficiencies
  13. Other comorbidities including:Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy
  14. Chronic kidney disease as defined by a GFR <60mL/min/1.73m2 44
  15. History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy
  16. Steroid dose >20mg/day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02424175

Contacts
Contact: Jessica Allegretti, MD 617-732-6389 jallegretti@partners.org
Contact: Joshua Korzenik, MD 617-732-6389 jkorzenik@partners.org

Locations
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Jessica Allegretti, MD    617-732-6389    jallegretti@partners.org   
Contact: Madeline Carrellas    617-732-9173    mcarrellas@partners.org   
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Joshua Korzenik, MD Brigham and Women's Hospital
  More Information

Responsible Party: Joshua Korzenik, Director, Crohn's and Colitis Center, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT02424175     History of Changes
Other Study ID Numbers: 2014P002475
Study First Received: April 18, 2015
Last Updated: April 5, 2017

Keywords provided by Joshua Korzenik, Brigham and Women's Hospital:
Fecal Transplant
Primary Sclerosing Cholangitis
Fecal Microbiota Transplantation

Additional relevant MeSH terms:
Cholangitis
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 18, 2017